In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Biogen Inc.

www.biogen.com

Latest From Biogen Inc.

Bookmark
  • Analysis

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

By John Davis

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.

 

Immune Disorders Clinical Trials
Bookmark
  • Analysis

ICER’s Biopharma Members: Why They Joined And What They Get

By Cathy Kelly

Biopharma’s funding support for the Institute for Clinical and Economic Review has been slightly above that of payers and providers for the past three to four years.

Health Technology Assessment Reimbursement
Bookmark
  • Analysis

Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches

By Andrew McConaghie, Brian Yang and Kevin Grogan
Scrip's Brian Yang describes what life is like in China as the authorities battle to contain the coronavirus, and drug developers race to find vaccine and anti-virals against the new threat. Plus news on Novartis' bold initiative with England on inclisiran, and what lies ahead for Biogen and Alzheimer's treatment in 2020.
International Commercial
Bookmark
  • Interviews

Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology

By Ian Haydock

Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.

Japan ImmunoOncology
See All

Company Information

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By